

CORRECTION

Open Access



Correction to: Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates

Xuefeng Zhang¹, Jing Wang¹, Jing Lu¹, Rongrong Li¹ and Shuli Zhao^{1,2*}

Correction

Ad-HBV is a product (T101) aiming to treat chronic HBV firstly developed by Transgene S.A., France then by Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China in China. So, in the originally published article [1], the “Ad-HBV” appeared throughout the whole paper for 41 times should be replaced by “T101”.

Additionally, in the “Acknowledgements” section in the originally published article, “The Ad-HBV were a kind gift from Xia Meng (Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China). We want to thank Zhiming Wang and Xiaomin Wang (Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., Tianjin, China) for teaching neutralization activity detection of anti-Ad antibodies” should be replaced by “We want to thank Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd., to provide us the opportunity to participate in the non-clinical safety assessment of T101, and most of the research work appeared in this paper came from the non-clinical safety assessment of T101”.

Received: 24 August 2018 Accepted: 27 August 2018
Published online: 03 September 2018

Reference

1. Zhang XF, et al. Immunogenicity of adenovirus-vector vaccine targeting hepatitis B virus: non-clinical safety assessment in non-human primates. *Virology J.* 2018;15:111. <https://doi.org/10.1186/s12985-018-1026-3>.

* Correspondence: shulizhao79@163.com

¹Jiangsu Tripod Preclinical Research Laboratories Co., Ltd., Nanjing 211800, China

²Nanjing First Hospital, Nanjing Medical University, 68 Changle Road, Nanjing 210006, China

